Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

At Coeptis Therapeutics, we are focused on discovering and developing new, transformative treatments that improve the lives of patients and their families. We strive to provide therapies that offer hope and real improvements in the care of cancer and inflammatory diseases.

Our vision is to be the premier biotechnology company in the oncology and inflammation space. Through innovation and collaboration, we aim to develop treatments that deliver meaningful clinical benefit to our patients.

Coeptis Therapeutics has been recognized with several awards including the 2019 National Institutes of Health New Innovator Award, the American Association for Cancer Research Innovation in Cancer Research Award, and the 2018 Venture Capital for Science Award for Oncology/Immunotherapy.